Background: Prices of anti-cancer drugs are skyrocking. We aimed to assess the clinical benefit of new drugs for treating advanced solid tumors at the time of their approval by the US Food and Drug Administration (FDA) and to search for a relation between price and clinical benefit of drugs. Results: The FDA approved 51 new drugs for advanced solid cancer from 2000 to 2015; we could evaluate the value of 37 drugs (73%). By the ESMO-MCBS, five drugs (14%) were grade one (the lowest), nine (24%) grade two, 10 (27%) grade three, 11 (30%) grade four and two (5%) grade five (the highest). Thus, 13 drugs (35%) showed a meaningful clinical benefit (scale levels 4 and 5). By the ASCO-VF which had a range of 3.4-67, the median drug value was 37 (interquartile range 20-52). We found no relationship between clinical benefit and drug price (P ¼ 0.9). No characteristic of drugs and of approval was significantly associated with clinical benefit.
Introduction
The concept of the value of drugs has recently dominated oncology. Massive investments in research yielded major advances in the comprehension of tumor biology, which has translated to an increase in number of new anti-cancer drugs approved by the US Food and Drug Association (FDA). Hence, new anticancer drugs have yielded high expectations from all stakeholders. Especially, drugs for personalized medicine-patients to be treated are selected on the basis of a predictive (genomic) biomarker-represent great hope for the oncology community [1] . Similarly, firstin-class drugs (relying on a new pharmacological mechanism of action) represent a measure of innovation success and could therefore have high value [2] . An increasing number of drugs has been approved by using pathways and designations to expedite drug approval [3] ; these are drugs that are intended for life-threatening conditions and unmet medical need.
The skyrocketing price of oncology drugs has led various stakeholders (patients, physicians and third-party payers) to criticize the pricing policies of manufacturers [4] and, combined with the high burden of cancer, has highlighted the question of the value of cancer drugs [5] . The high price of drugs is often justified by the need to support research and development, but an analysis of the most transformative drugs showed that, actually, government-funded academic research was the primary source of drug innovation [6] .
A critical question for the oncology community is how to assess the value of drugs. Two important oncology societies have recently taken a step forward in this endeavor: The American Society of Clinical Oncology (ASCO) published its Conceptual Framework to Assess the Value of Cancer Treatment Options (ASCO-VF) [7] , which was updated in 2016 [8] , and the European Society for Medical Oncology developed its Magnitude of Clinical Benefit Scale (ESMO-MCBS) for drugs indicated in the treatment of solid cancer [9] . Both scales have been designed with the aim of evaluating the value of anti-cancer drugs by '[balancing] the magnitude of its clinical benefit [. . .] against its cost ' [9] .
This study aimed to describe the clinical benefit of new drugs for treating advanced solid cancer that were recently approved by the FDA and to search for a relationship between clinical benefit and price of drugs and for characteristics associated with clinical benefit. We restricted this study to drugs for treating advanced solid cancer because the (i) ESMO-MCBS is applicable only for drugs treating solid cancers and (ii) the vast majority of new anticancer drugs are indicated in the advanced setting.
Methods

List of drugs
We included all new drugs (new molecular entities and novel biologics) indicated for treating advanced solid cancer that were approved by the FDA between 2000 and 2015.
Description of the ASCO-VF net health benefit (NHB)
The ASCO-VF NHB has three main components: (i) magnitude of treatment effect, (ii) toxicity and (iii) bonus points [8] . The magnitude of treatment effect is assessed by overall survival (OS) if reported; if OS is not reported, progression-free survival (PFS) is used; and if neither OS nor PFS are reported, overall response rate (ORR) is used. Treatment effect size for OS and PFS is quantified by hazard ratios (HR) and difference in median survival time and weighted by type of endpoint. For instance, an HR of 0.7 for OS yields 30 points, but the same HR for PFS would yield only 21 points.
The toxicity score ranges from -20 to þ20. The value depends on the frequency and severity of toxic effects. A null value corresponds to a new drug with similar toxicity as for the control. Negative points are for a new drug associated with high toxicity and positive points are awarded if the new drug reduces toxicity as compared with the control.
If a treatment is associated with long-term benefit, it can be awarded 'tail of the curve' bonus points (16 points for PFS or 20 for OS). Three other possible bonuses include a ten-point bonus for treatments improving cancer-related symptoms, another ten-point bonus for improving quality-of-life (QoL) and another ten-point bonus for improving treatment-free interval. These bonuses can be cumulative. The sum of the magnitude of treatment effect, toxicity and bonus points gives the NHB (ASCO-VF NHB) [8] .
Description of the ESMO-MCBS
The ESMO-MCBS has two main components: (i) a preliminary score based on the clinical benefit and (ii) modification (upgrade and downgrade) of the primary score based on the toxicity and QoL, which yields the final score based on five-point scale ranging from one, lowest grade, to five, highest grade [9] . Levels four and five correspond to a meaningful clinical benefit [9, 10] . In the first part, a preliminary score is calculated on the basis of the clinical benefit of the drug according to the primary endpoint of the study. The treatment effect size is quantified by either (i) the lower limit of the 95% confidence interval (CI) for the HR and by differences in median survival or (ii) by the increase in survival at a fixed time (two or three years depending on the median survival time with the standard treatment). When HRs and the increase in survival at a fixed time yield different results, the best score is used. With OS, the preliminary value ranges from one to four and could be upgraded if the treatment improves QoL or reduced grade three to four toxicity affecting daily well-being. Hence, the final value for drugs evaluated with OS ranges from one to five. For drugs evaluated with PFS, the preliminary value ranges from one to three and could be upgraded with the same conditions as for OS. However, the score could be downgraded with increased toxicity or if a drug leads to only a benefit for PFS (i.e. without a benefit for OS) and fails to show an improvement in QoL. The maximal value for drugs evaluated with PFS is thus four. The ESMO-MCBS indicates that levels four and five correspond to ASCO guidelines for meaningful clinical benefit [9, 10] .
Grading of the clinical benefit drug by using the ASCO-VF and ESMO-MCBS
We graded the drugs with the ASCO-VF and ESMO-MCBS based on data from the pivotal clinical trials submitted to the FDA for approval and described in the FDA medical review (retrieved from Drugs@fda website). Scores were assessed by one investigator and checked by a second one, with discrepancies resolved by a senior investigator.
Approval characteristics
We assessed whether the drug was granted with one of the five FDA pathways and designations to expedite drug approval (orphan drug status, fast-track, priority review, breakthrough designation and accelerated approval).
Drug prices
We re-used data from the DrugAbacus database to obtain the price of drugs in three markets: US Medicare, US Veterans Health Administration and the United Kingdom [11] . For drugs not listed in the DrugAbacus database, we computed the cost in US Medicare terms by using publicly available data and the same methods as used in the DrugAbacus database. The primary analysis was pre-specified as using prices by the US Medicare system because it had the fewest missing values.
Statistical analyses
The association between the clinical benefit of drugs and their characteristics was tested by Mann-Whitney-Wilcoxon and Fisher exact tests. We investigated the relation with drug prices by simple linear regression. P <0.05 was considered statistically significant.
Results
Number and characteristics of new drugs
From 2000 to 2015, the FDA approved 51 new drugs for treating advanced solid tumors (supplementary Figure S1 , available at Annals of Oncology online). Three approvals were discontinued as of 6 October 2016 and thus were removed from our sample. Furthermore, we could not assess the value of 11 drugs (23%) because the pivotal trial was not a head-to-head RCT, had a noninferiority design or did not report one of the three endpoints used in the value scales (OS, PFS and ORR). Thus, we analyzed data for 37 drugs. The most frequent indications were colorectal (N ¼ 6, 16%) and breast (N ¼ 6, 16%) cancers (supplementary Table S1 , available at Annals of Oncology online).
Clinical benefit of new drugs
By the ASCO-VF, the median NHB of drugs was 37 [interquartile range 20-52; range 3.4-66.5] (supplementary Table S2 , available at Annals of Oncology online and Figure 1) . The median treatment effect score was 34 [interquartile range 23-42] and the median toxicity score was -5 [-13 to -2]. Bonus points for a tail on PFS curves were granted for 14 drugs (38%) and for OS curves for four drugs (11%); for palliation symptoms for two drugs (5%); and for improvement in QoL for four drugs (11%). No drugs received bonus points for treatment-free interval. By the ESMO-MCBS, five drugs (14%) were grade one (the lowest), nine (24%) grade two, 10 (27%) grade three, 11 (30%) grade four and two (5%) grade five (the highest). Thus, 13 drugs (35%) had a meaningful clinical benefit (levels four and five). Toxicity assessment downgraded the value for two drugs (5%) and upgraded it for one drug (3%). Quality of life assessment downgraded the value for four drugs (11%) and upgraded it for six drugs (16%). Results of assessment of value for each drug are provided in Table 1 .
Characteristics associated with drug clinical benefit
We found no differences in ASCO-VF scores by innovation degree (first-in-class versus advance or addition to class: 37 versus 38, P ¼ 0.29); orphan status (38 versus 36, P ¼ 0.56); priority review (37 versus 39, P ¼ 0.69); breakthrough designation (29 versus 52, P ¼ 0.24); accelerated approval (22 versus 40, P ¼ 0.13); or fast-track (46 versus 34, P ¼ 0.15). The presence of a pharmacogenomic biomarker in the drug label where also not statistically associated with drug value albeit drugs with a biomarker had a median of 44 versus 31 for those without, P ¼ 0.06, supplemen tary Figure S2 , available at Annals of Oncology online. Results were similar with ESMO-MCBS scores (supplementary Figure  S3 , available at Annals of Oncology online).
Relation between price and value of drugs
We found no relation between ASCO-VF score and price as determined by US Medicare [R 2 ¼ 0, P ¼ 0.93] (Figure 2 ), nor any relation between price and value whatever the scale used (ASCO-VF or ESMO-MCBS) or system used to determine the price (US Medicare, US Veterans Health Administration or United Kingdom).
Discussion
In our review of all anticancer agents approved by the FDA be- meaningful clinical benefit according to the ESMO-MCBS; (ii) drug price and clinical benefit were not related by the two scales and the three pricing systems; and (iii) drug clinical benefit was not associated with any drug characteristics. Especially, we found no significant difference for personalized medicine drugs and first-in-class drugs.
Our results are consistent with a recent review finding that only 31% of drugs examined in published randomized controlled trials of four cancers (breast, colorectal, non-small cell lung and pancreas) had meaningful clinical benefit according to the ESMO-MCBS [10] . Another recent overview of clinical trials supporting FDA-approval cancer drugs (new drugs or new indications) from April 2014 to February 2016 found that half met the ASCO-VF meaningful goals for future clinical trials for PFS and one fifth for OS [12] .
The absence of a price-clinical benefit relation could be theoretically surprising. However, our results agree with previous studies [13] . Clinical benefit was not assessable for 20% of drugs mainly because the drugs were approved on the basis of a single-arm trial. This situation is not rare in oncology, especially for orphan drugs [14] , so assessing clinical benefit in this situation is highly problematic-at least at the time of marketing authorization.
The ASCO-VF and the ESMO-MCBS yielded some discrepancies which are not surprising given the differences in their construction and their somewhat different goals. The ASCO-VF is more patient-oriented and was developed to 'assist in facilitating shared decision-making with patients about clinical benefits and costs,' [7, 8] whereas the ESMO-MCBS is more societal-oriented and was developed to 'frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care' [9] . Especially, the ESMO-MCBS uses the primary endpoint (often PFS), whereas the ASCO-VF uses OS if reported. However, in many cases OS was not usable to score drugs because of cross-over from experimental to control arm or because the OS were not enough mature at the time of approval. This echoes the difficulties to choose OS as a primary endpoint in many advanced cancer settings. Our study encompasses a large period of time and used two validated scales, including the 2016 update of the ASCO-VF. However, it has some limitations. First, defining the exact clinical benefit of a drug is complex [15] . In this study, we used two scales that were previously tested and validated by various stakeholders and international experts and our results were similar whatever the scale used. The assessment of value depends on accurate reporting and analysis of clinical trial data. Notably, treatment effects have been found greater in published trials than in FDA documents [16] . In this study, we used FDA documents as the primary source of data to limit reporting biases. The benefit of a drug refers to a benefit averaged over all patients being treated but it is well known that treatment effects are heterogeneous and some patients could derive a great benefit from a drug with a low value score.
Determining the price of a drug is complex because different prices are available depending on the country and even within the US depending on the entity that purchases the drug. Furthermore, there is only limited transparency in drug pricing because the prices available usually do not account for managed-entry agreements or other discounts granted to buyers by drug manufacturers (which are not known to the public). In our study, we used two countries and three different pricing systems, including one with negotiated prices (US Veterans Health Administration). Because the results of our analyses did not depend on the choice of pricing system, we are confident that this limitation did not impact our study.
The clinical benefit score of drugs is dynamic by nature as acknowledged by the ASCO [8] because of different reasons:
a. Within a trial, efficacy results (especially OS results) could and will evolve with time as more events occur; b. As new clinical trials are conducted, the pooled estimate of efficacy results will also evolve; c. A drug could have subsequent supplemental approvals for new indications, each one being associated with a different magnitude of clinical benefit compared with its original indication. This point is precisely the central argument for having an indication-specific price of drugs [5] .
Here, we focused on the first indication of new drugs and evaluated the clinical benefit based on data submitted for approval because this reflects the entry into the market. How this benefit evolves over time and with possible new indications is of interest but is out of the scope of our study. Recently, a live cumulative network meta-analysis was proposed to reflect an up-to-date summary of trial evidence for a given indication [17] . Similarly, the clinical benefit of a drug is relative to the control and evolves with time as more evidence and more alternatives are available. ESMO has planned to score all new drugs approved after 1 January 2016 [18] and this could be incorporated in a live cumulative assessment of drugs clinical benefit.
Conclusion
Patients, clinicians and policy-makers are involved in a salient debate on the clinical benefit, price and value of drugs. Regarding the evidence for new cancer drugs, the bar has been dropping [19] , which has been justified by the high benefit of new drugs. We showed, however, that the price of drugs was not related to their benefit to society and patients.
